1.
J Law Med Ethics
; 51(S1): 136-147, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38156353
RESUMO
Cuba faces a dilemma between continuing its current portfolio of biotechnology drugs and vaccines with lower profitability or renewing its product portfolio with the associated costs and risks.
